<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04236856</url>
  </required_header>
  <id_info>
    <org_study_id>104-08660</org_study_id>
    <nct_id>NCT04236856</nct_id>
  </id_info>
  <brief_title>CorPath® GRX Neuro Study</brief_title>
  <official_title>An Evaluation of Effectiveness and Safety of the CorPath® GRX System in Endovascular Embolization Procedures of Cerebral Aneurysms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corindus Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corindus Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the effectiveness and safety of&#xD;
      robotic-assisted endovascular embolization procedures compared to objective performance&#xD;
      criteria for traditional, manual operation based on the scientific literature.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single-arm, international, multi- center, non-inferiority study to&#xD;
      evaluate the effectiveness and safety of the CorPath GRX System for endovascular cerebral&#xD;
      aneurysm embolization compared to historical controls. Subject selection requires a clinical&#xD;
      indication for endovascular coil and/or stent-assist coiling embolization of cerebral&#xD;
      aneurysms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 21, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a prospective, single-arm, international, multi- center, non-inferiority study to evaluate the effectiveness and safety of the CorPath GRX System for endovascular cerebral aneurysm embolization compared to historical controls.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedural Technical Success.</measure>
    <time_frame>Measured from the start of the procedure to the end of the procedure.</time_frame>
    <description>The primary effectiveness endpoint will be defined as successful completion of the robotic-assisted endovascular procedure absent any unplanned conversion to manual for guidewire or microcatheter navigation, embolization coil(s) or intracranial stent(s) deployment, or an inability to navigate vessel anatomy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Inta- and Peri-procedural Events.</measure>
    <time_frame>Measured from the start of the procedure through 24 hours or discharge.</time_frame>
    <description>The primary safety endpoint will be a composite of intra- and periprocedural events, including target aneurysmal rupture, vessel perforation or dissection, and thromboembolic event with neurological decline within 24-hours post- procedure or hospital discharge, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Robotically Navigate Device to the Target Aneurysm</measure>
    <time_frame>Measured from the start of the procedure to the end of the procedure.</time_frame>
    <description>Defined as successful advancement of device to the target aneurysm robotically.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Robotically Navigate Device into the Target Aneurysm</measure>
    <time_frame>Measured from the start of the procedure to the end of the procedure.</time_frame>
    <description>Defined as successful navigation of device into the target aneurysm robotically</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Robotically Deploy Therapeutic Device into the Target Aneurysm</measure>
    <time_frame>Measured from the start of the procedure to the end of the procedure.</time_frame>
    <description>Defined as successful deployment of therapeutic device into the target aneurysm robotically</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Procedure Time</measure>
    <time_frame>Measured from the start of the procedure to the end of the procedure.</time_frame>
    <description>Defined as the time measured from the insertion of the access sheath/catheter until the removal of the microcatheter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopy Time</measure>
    <time_frame>Measured from the start of the procedure to the end of the procedure.</time_frame>
    <description>Total fluoroscopy utilized during the procedure as recorded by the Imaging System</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Radiation Exposure</measure>
    <time_frame>Measured from the start of the procedure to the end of the procedure.</time_frame>
    <description>DAP (dose-area-product) and/or AK (Air Kerma) as recorded during the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast Fluid Volume</measure>
    <time_frame>Measured from the start of the procedure to the end of the procedure.</time_frame>
    <description>Total contrast used during the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Measured from the start of the procedure through 24 hours or discharge.</time_frame>
    <description>All adverse events (AEs) from the start of the CorPath GRX procedure until the end of the study will be summarized;</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Intracranial Aneurysm</condition>
  <condition>Subarachnoid Hemorrhage</condition>
  <condition>Headache</condition>
  <arm_group>
    <arm_group_label>Robotic Endovascular Procedure</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects with a clinical indication for endovascular coil and/or stent assisted coiling embolization of cerebral aneurysms will be treated using the CorPath GRX System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Robotic Endovascular Procedure</intervention_name>
    <description>After providing written informed consent, subjects with cerebral aneurysms may have their aneurysm treated using the CorPath GRX System.</description>
    <arm_group_label>Robotic Endovascular Procedure</arm_group_label>
    <other_name>CorPath GRX System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years.&#xD;
&#xD;
          2. At least one cerebral aneurysm (unruptured) with indication for endovascular&#xD;
             treatment; dome to neck ratio &gt;1.5 or aneurysm neck width &gt;4.0 mm.&#xD;
&#xD;
          3. The Investigator deems the procedure appropriate for both manual or robotic-assisted&#xD;
             endovascular treatment.&#xD;
&#xD;
          4. The conscious subject has been informed of the nature of the study, agrees to its&#xD;
             provisions and has provided written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Failure / unwillingness of the subject to provide informed consent, unless the EC has&#xD;
             waived informed consent.&#xD;
&#xD;
          2. The Investigator determines that the subject or the neurovascular anatomy is not&#xD;
             suitable for robotic-assisted endovascular treatment.&#xD;
&#xD;
          3. Women who are pregnant.&#xD;
&#xD;
          4. Persons under guardianship or curatorship.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel Piotin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Interventional Neuroradiologisit &amp; Director, Foundation Rothschild</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Corindus Clinical Affairs</last_name>
    <phone>818-292-5410</phone>
    <email>corclinicalaffairs@siemens-healthineers.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gold Coast University Hospital</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Rapier</last_name>
      <phone>1300 744 284</phone>
    </contact>
    <investigator>
      <last_name>Hal Rice, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen Liu</last_name>
    </contact>
    <investigator>
      <last_name>Julian Spears, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <state>CA</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atika Talbi</last_name>
      <phone>+33 6 29840331</phone>
      <email>atika.talbi@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Nader Sourour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Fondation Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75940</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michel Piotin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron University Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eila Rivera</last_name>
      <email>eriverboix@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Marc Ribo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Clinical Hospital of Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofia Pérez</last_name>
      <email>sofiperez28@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Mario Galdámez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Lawton MT, Vates GE. Subarachnoid Hemorrhage. N Engl J Med. 2017 Jul 20;377(3):257-266. doi: 10.1056/NEJMcp1605827. Review.</citation>
    <PMID>28723321</PMID>
  </reference>
  <reference>
    <citation>Lantigua H, Ortega-Gutierrez S, Schmidt JM, Lee K, Badjatia N, Agarwal S, Claassen J, Connolly ES, Mayer SA. Subarachnoid hemorrhage: who dies, and why? Crit Care. 2015 Aug 31;19:309. doi: 10.1186/s13054-015-1036-0.</citation>
    <PMID>26330064</PMID>
  </reference>
  <reference>
    <citation>Connolly ES Jr, Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, Higashida RT, Hoh BL, Kirkness CJ, Naidech AM, Ogilvy CS, Patel AB, Thompson BG, Vespa P; American Heart Association Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Clinical Cardiology. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/american Stroke Association. Stroke. 2012 Jun;43(6):1711-37. doi: 10.1161/STR.0b013e3182587839. Epub 2012 May 3.</citation>
    <PMID>22556195</PMID>
  </reference>
  <reference>
    <citation>Steiner T, Juvela S, Unterberg A, Jung C, Forsting M, Rinkel G; European Stroke Organization. European Stroke Organization guidelines for the management of intracranial aneurysms and subarachnoid haemorrhage. Cerebrovasc Dis. 2013;35(2):93-112. doi: 10.1159/000346087. Epub 2013 Feb 7. Review.</citation>
    <PMID>23406828</PMID>
  </reference>
  <reference>
    <citation>Keedy A. An overview of intracranial aneurysms. Mcgill J Med. 2006 Jul;9(2):141-6.</citation>
    <PMID>18523626</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 2, 2020</study_first_submitted>
  <study_first_submitted_qc>January 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2020</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share IPD.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

